Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances

Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors. The landscape of LDL-C lowering therapy is rapidly evolving, and during this activity, experts discuss and offer their perspectives on the optimization and integration of these advances to patient care to help address current gaps. In addition, the activity includes the perspectives of a patient champion to illustrate current challenges in the prevention and management of ASCVD in women.

The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, and organized into different segments to facilitate learning.

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including endocrinologists, cardiologists, internists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, and physician assistants.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the burden of ASCVD risk in women, and challenges with optimizing statin therapy.
  • Explain the need for the early and adequate intensification of LDL-C lowering therapy beyond statins in women to address ASCVD risk.
  • Evaluate the efficacy and safety of PCSK9 inhibitors across trial and real-world evidence.
  • Discuss the rationale, efficacy, and safety of novel LDL-C lowering agents and their potential impact in addressing current gaps in lipid-lowering therapy in women.
  • Select individualized treatment strategies to optimize lipid-lowering therapy in women that prioritize the early initiation and intensification of therapy to reduce ASCVD risk. 
Course summary
Available credit: 
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 Participation
Course opens: 
Course expires: 


Erin D. Michos, MD, MHS
Director of Women's Cardiovascular Health
Johns Hopkins University School of Medicine
Baltimore, MD


Eugenia Gianos, MD
Professor of Cardiology
Zucker School of Medicine, Northwell Health/Lenox Hill Hospital
New York, NY

Payal Kohli, MD, FACC
Cardiologist, Medical Director
Cherry Creek Heart
Denver, CO

Agnes Czuchlewski
WomenHeart Patient Champion

1.5 hours


Supported by an educational grant from Esperion Therapeutics, Inc.

A picture containing text, clipart    Description automatically generated

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.


PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-23-332-H01-P. Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.


There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from December 21, 2023 through December 21, 2024.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at For additional information about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.


PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Michos, faculty for this educational activity, has the following relevant financial relationships:

Consultant, Advisor, Speaker: AstraZeneca, Amarin, Amgen, Bayer, Boehringer Ingelheim, Esperion, Edwards Life Science, Medtronic, Novartis, Novo Nordisk, Pfizer

Dr. Gianos, faculty for this educational activity, has the following relevant financial relationships:

Other: Kaneka, AstraZeneca, Med-IQ

Dr. Kohli, faculty for this educational activity, has the following relevant financial relationships:

Consultant, Advisor, Speaker: Boston Scientific, Amarin, Esperion, Astra Zeneca, Merck, Astra Zeneca, Zoll, Boston Scientific, Esperion, Novartis, Amgen, GE/SkyWord
Stock options: Doximity

Ms. Czuchlewski, faculty for this educational activity, has nothing to disclose. 


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Available Credit

  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.